{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-020384","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2026-06-12T12:00:17+00:00","discovered_at":"2026-06-12T12:05:00.289974+00:00","generated_at":"2026-06-12T12:06:06.784587+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCardia regains Nasdaq minimum equity compliance after $4.9M ATM raise","bullets":["Nasdaq extended compliance deadline to Oct 7, 2026 after company submitted plan to regain minimum $2.5M equity.","Raised ~$4.9M net through ATM sale of 4.0M shares at avg $1.27 from Apr 1 to Jun 5, 2026.","Company believes stockholders' equity now exceeds $2.5M, meeting Nasdaq continued listing requirement.","Nasdaq will monitor compliance; delisting risk remains if not sustained at next periodic report."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-020384","json":"https://secwatch.observer/filing/0001437749-26-020384.json","markdown":"https://secwatch.observer/filing/0001437749-26-020384.md","text":"https://secwatch.observer/filing/0001437749-26-020384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926020384/0001437749-26-020384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926020384/bcda20260612_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:06:06.784587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf23dda14dace40f82b3fec5c9631fd805331bd6","claim":"BioCardia, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"June 9, 2026, received written notice that, based on review of the compliance plan, the Nasdaq staff granted the Company an extension to October 7, 2026 to regain compliance with the Rule. The Company is filing this Current Report on Form 8-K (this “Report”) to provide an update to its compliance with continued listing requirements as set forth in Nasdaq Listing Rule 5550(b)(1). On June 8, 2026, the Company filed an 8-K and issued a press release announcing that the Company sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. The shares were sold pursuant to the Company","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774926020384/0001437749-26-020384-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}